2-硝基-4-溴苯腈 | 79603-03-5

• 物质功能分类: 有机原料 - 烃类化合物及其衍生物 - 烃类硝化物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-硝基-4-溴苯腈
• 中文别名: 4-溴-2-硝基苯甲腈
• 英文名称: 4-bromo-2-nitrobenzonitrile
• CAS: 79603-03-5
• 化学式: C₇H₃BrN₂O₂
• mdl: MFCD00087225
• 分子量: 227.017
• InChiKey: IOBYLOUUUJPZEO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  69.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2926909090
• 储存条件：
  室温且干燥环境下使用。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-bromo-2-nitrobenzonitrile
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-bromo-2-nitrobenzonitrile
CAS number: 79603-03-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H3BrN2O2
Molecular weight: 227.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-硝基-4-溴苯腈 在 盐酸 、 tin(ll) chloride 作用下， 以 水 为溶剂， 反应 1.0h， 以92%的产率得到2-氨基-4-溴苯腈
  参考文献：
  名称：

  유기발광 화합물 및 이를 포함하는 유기전계발광소자

  摘要：

  本发明涉及如下式[化学式1-1]至[化学式1-2]所示的有机发光化合物，采用该化合物的有机电致发光器件具有优异的发光效率，同时还能实现低电压驱动，从而具有改善的功率效率和长寿命特性。[化学式1-1] [化学式1-2]

  公开号：

  KR20150043571A
• 作为产物：
  描述：

  N-(3-bromophenyl)-2-hydroxyiminacetamide 在 2,6-二甲基吡啶 、 三氟甲磺酸酐 、 硫酸 、 盐酸羟胺 、 三氟乙酸 作用下， 以 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 19.17h， 生成 2-硝基-4-溴苯腈
  参考文献：
  名称：

  Synthesis and Dual D₂ and 5-HT_1A Receptor Binding Affinities of 7-piperazinyl and 7-piperidinyl-3,4-dihydroquinazolin-2(1H)-ones

  摘要：

  一系列新的7-哌嗪基和7-哌啶基-3,4-二氢喹唑啉-2(1H)-酮已被合成。所述化合物在结构上与阿多拉嗪相关，后者是一种潜在的不典型抗精神病药物，具有强效的D2受体拮抗剂和5-HT1A受体激动剂特性。制备了适当修饰的芳基溴化物，并与叔丁基哌嗪-1-羧酸酯缩合，得到高级中间体哌嗪基-3,4-二氢喹唑啉-2(1H)-酮。同样，Suzuki-Miyaura交叉偶联反应中，环状乙烯基硼酸盐与适当的芳基溴化物反应，得到哌啶基-3,4-二氢喹唑啉-2(1H)-酮。通过哌嗪基和哌啶基-3,4-二氢喹唑啉-2(1H)-酮与适当设计的联芳基醛的还原胺化反应，完成了这些目标化合物的合成。所述化合物被筛选为D2和5-HT1A受体结合亲和力。结构-活性关系研究表明，环戊烯基吡啶和环戊烯基苄基对这些化合物的双重D2和5-HT1A受体结合亲和力有显著贡献。

  DOI：

  10.2174/15734064113096660046

文献信息

• 一种医药中间体噁唑类化合物的合成方法
  申请人：连良清

  公开号：CN105906578B

  公开（公告）日：2018-08-07

  本发明涉及一种可用作医药中间体的下式(III)所示的噁唑类化合物的合成方法，所述方法包括：在氮气氛围下，于有机溶剂中，在催化剂、有机配体、氧化剂和助剂的存在下，下式(I)化合物和下式(II)化合物进行反应，反应结束后经后处理，从而得到所述式(III)化合物，其中，R1、R2各自独立地选自H、C1‑C6烷基、C1‑C6烷氧基或卤素；X为卤素。所述方法通过合适的底物选择，以及通过催化剂、有机配体、氧化剂、助剂和有机溶剂的综合协同，从而成功实现了噁唑类化合物的高收率制备，且反应速度快、工艺简单，极具工业应用潜力，市场前景十分广阔。
• CsF–Al2O3 mediated rapid condensation of phenols with aryl halides: comparative study of conventional heating vs. microwave irradiation
  作者：Jhillu S. Yadav、Basi V. Subba Reddy

  DOI：10.1039/b001824o

  日期：——

  Biaryl ethers and thio ethers are formed in high yields by the condensation of phenols and thiophenols with electron-deficient aryl halides using CsF supported on Al2O3 under microwave irradiation in solvent-free conditions.

  双芳基醚和硫醚在无溶剂条件下，通过酚和硫酚与缺电子芳基卤化物在无溶剂条件下利用负载于氧化铝上的氟化铯在微波辐射下缩合，能够以高产率生成。
• [EN] THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS OXY-PHÉNYL-ARYLES THÉRAPEUTIQUES ET LEUR UTILISATION
  申请人：CANCER REC TECH LTD

  公开号：WO2009053694A1

  公开（公告）日：2009-04-30

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain oxy phenyl aryl compounds (referred to herein as OPA compounds), as described herein, which, inter alia, inhibit Checkpoint Kinase 2 (CHK2) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK2 kinase function, and in the treatment of diseases and conditions that are mediated by CHK2, that are ameliorated by the inhibition of CHK2 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation.

  本发明总体涉及治疗化合物领域，更具体地涉及如本文所述的某些氧基苯基芳基化合物（以下简称OPA化合物），其中，抑制检查点激酶2（CHK2）激酶功能。本发明还涉及包含此类化合物的药物组合物，以及使用此类化合物和组合物，在体内外抑制CHK2激酶功能，以及治疗由CHK2介导的疾病和状况，包括通过抑制CHK2激酶功能而改善的疾病和状况，等等，包括诸如癌症等增殖性疾病，可选地与另一剂联合使用，例如，（a）DNA拓扑异构酶I或II抑制剂；（b）DNA损伤剂；（c）抗代谢物或TS抑制剂；（d）针对微管的药剂；（e）电离辐射。
• Quinazoline derivatives
  申请人：——

  公开号：US20040116422A1

  公开（公告）日：2004-06-17

  A compound of the formula (I) 1 or a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, an optically active compound thereof, a racemate thereof or a diastereomer mixture thereof has a superior tyrosine-specific protein kinase inhibitory activity and is useful as a pharmaceutical agent, particularly as an agent for the prophylaxis or treatment of various cancers, psoriasis or diseases caused by arteriosclerosis, and the like.

  式（I）的化合物或其药学上可接受的盐、水合物、溶剂合物、光学活性化合物、消旋体或其二对映异构体混合物具有优越的酪氨酸特异性蛋白激酶抑制活性，并且可用作药物剂，特别是作为各种癌症、银屑病或由动脉硬化引起的疾病的预防或治疗剂。
• [EN] TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS<br/>[FR] COMPOSÉS TRICYCLIQUES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA PHOSPHODIESTERASE
  申请人：PFIZER

  公开号：WO2016203347A1

  公开（公告）日：2016-12-22

  The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents A, R1, R2, R3a, R3b, R4a, R4b and n are as defined herein. The inventions also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds and methods of preparing the compounds.

  本发明涉及以下式I的化合物或其药用盐，其中取代基A、R1、R2、R3a、R3b、R4a、R4b和n的定义如本文所述。该发明还涉及包含这些化合物的药物组合物、使用这些化合物的治疗方法以及制备这些化合物的方法。